✦ LIBER ✦

A Phase I Study of Gemtuzumab Ozogamicin in Combination With a Myeloablative Conditioning (MAC) Regimen and alloSCT in Children With High-Risk CD33+ AML: A New Targeted Immunochemotherapy Conditioning Regimen (GO-BU/CY)

✍ Scribed by P. Satwani; F. Dela Cruz; J. Le Gall; Z. Jin; M. Bhatia; J.H. Garvin; D. George; J. Schwartz; C. van de Ven; E. Morris; L.A. Baxter-Lowe; M.S. Cairo

Book ID: 116282226
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 58 KB
Volume: 17
Category: Article
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2010.12.283

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase I Study of Gemtuzumab Ozogamicin

A Phase I Study of Gemtuzumab Ozogamicin (GO) in Combination with Busulfan and Cyclophosphamide (Bu/Cy) and Allogeneic Stem Cell Transplantation in Children with Poor-Risk CD33+ AML: A New Targeted Immunochemotherapy Myeloablative Conditioning (MAC) Regimen

✍ Prakash Satwani; Monica Bhatia; James H. Garvin Jr.; Diane George; Filemon Dela 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 146 KB

202: Preliminary Results of a Phase I St

202: Preliminary Results of a Phase I Study of Immuno-Chemotherapy (CTX) Conditioning with Gemtuzumab Ozogamicin (GO), Busulfan (Bu) and Cyclophosphamide (Cy) Followed by Allogeneic Stem Cell Transplantation (AlloSCT) in Pediatric Recipients with High Risk (HR) CD33+ Acute Myelogenous Leukemia (AML)

✍ I. Waxman; M. Bhatia; E. Qualter; Z.Z. Jin; V. Kohl; L. Baldinger; J. Guerra; J. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 59 KB